6534 — CH Biotech R&D Co Cashflow Statement

0.000.00%

Last trade - 00:00

Basic MaterialsBalancedSmall CapNeutral

Annual cashflow statement for CH Biotech R&D Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	127	360	566	579	593
Depreciation
Amortisation
Non-Cash Items	22.3	13.3	13.3	4.92	-6.29
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-14.9	-205	-19.8	-90.5	-238
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	233	264	699	659	538
Capital Expenditures	-109	-45	-117	-115	-590
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	0.037	0.225	-0.075	-28.2	-4.81
Acquisition of Business
Sale of Fixed Assets
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-109	-44.8	-117	-143	-595
Financing Cash Flow Items	—	—	—	—	1.02
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-81.7	-222	-375	-107	-406
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	42	-3	209	410	-461